

## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.,	CONFIRMATION NO.
10/773,302	02/09/2004	Thomas Jenuwein	0652.1670002/JUK/JCI	8734
26111	7590 03/15/2006	•	EXAMINER ,	
STERNE, KESSLER, GOLDSTEIN & FOX PLLC 1100 NEW YORK AVENUE, N.W.			MARTINELL, JAMES	
			· · ·	
	ON, DC 20005	•		PAPER NUMBER
	,		1634	
			DATE MAILED: 03/15/2006	, , ,

Please find below and/or attached an Office communication concerning this application or proceeding.

8		Application No.	Applicant(s)			
Office Action Summary		10/773,302	JENUWEIN ET AL.			
		Examiner	Art Unit			
		James Martinell	1634			
	The MAILING DATE of this communication a					
Period for Reply						
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REF CHEVER IS LONGER, FROM THE MAILING nsions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication. O period for reply is specified above, the maximum statutory perior are to reply within the set or extended period for reply will, by state reply received by the Office later than three months after the mailed patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 1.136(a). In no event, however, may a reply be tin ord will apply and will expire SIX (6) MONTHS from ute, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status						
1)	Responsive to communication(s) filed on					
		is action is non-final.				
	, <del>_</del>					
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Dispositi	ion of Claims					
4)⊠	4)⊠ Claim(s) <u>20-45</u> is/are pending in the application.					
	4a) Of the above claim(s) is/are withdrawn from consideration.					
	is/are allowed.					
6)□	Claim(s) is/are rejected.					
7)	Claim(s) is/are objected to.					
8)⊠	Claim(s) 20-45 are subject to restriction and	or election requirement.				
Applicati	ion Papers					
9)[	The specification is objected to by the Exami	ner.				
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority ι	under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
Attachmen		_				
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da				
3) 🔲 Infor	mation Disclosure Statement(s) (PTO-1449 or PTO/SB/0 r No(s)/Mail Date		ratent Application (PTO-152)			

Application/Control Number: 10/773,302

Art Unit: 1634

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 20-32, drawn to nucleic acids encoding SEQ ID NO: 2 (*i.e.*, protein EZH2), vectors, methods for producing vectors, transformed host cells, and methods for producing polypeptides of SEQ ID NO: 2.

Group II, claim(s) 33-45, drawn to nucleic acids of SEQ ID NO: 5, vectors, methods for producing vectors, transformed host cells, and methods for producing polypeptides encoded by SEQ ID NO: 5 (*i.e.*, EZH1).

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: SEQ ID NO: 2 of Group I is encoded by SEQ ID NO: 1 among other nucleic acids. SEQ ID NO: 2 is EXH2 (see Figure 8). SEQ ID NO: 5 encodes EZH2 and differs significantly from SEQ ID NO: 1 (see the alignment in Figure 8). Thus, the two groups do not share a special technical feature. Prior art may be found and applied to Group I that may not be relevant for Group II. In addition, prior art may be found and applied to Group II that may not be relevant for Group II.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their different classification and recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Application/Control Number: 10/773,302

Art Unit: 1634

·/. . ~

To search any two groups as outlined above would create an undue burden for the U.S. PTO

because the searches of the non-patent literature are not only non-overlapping to any appreciable extent,

but are also divergent in nature.

Applicant is advised that the reply to this requirement to be complete must include an election of

the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named

inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of

inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37

CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should

be directed to James Martinell whose telephone number is (571) 272-0719. The fax phone number for

Examiner Martinell's desktop workstation is (571) 273-0719. Only documents such as those intended for

use in a personal or telephone interview should be faxed to the examiner's desktop workstation. Any

Official Communication to the USPTO should be faxed to (571) 273-8300.

The examiner works a flexible schedule and can be reached by phone and voice mail.

Alternatively, a request for a return telephone call may be e-mailed to james.martinell@uspto.gov. Since

e-mail communications may not be secure, it is suggested that information in such requests be limited to

name, phone number, and the best time to return the call.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram

Shukla, can be reached on (571) 272-0735.

Jámes Martinell, Ph.I Primary Examiner

Art Unit 1634

7/11/06

Page 3